Status:

COMPLETED

Ketoconazole in Treating Participants With Ongoing EGFR Inhibitor-Induced Rash

Lead Sponsor:

Mayo Clinic

Collaborating Sponsors:

National Cancer Institute (NCI)

Conditions:

Malignant Neoplasm

Eligibility:

All Genders

18+ years

Phase:

EARLY_PHASE1

Brief Summary

This early phase I trial studies the side effects of ketoconazole and how well it works in treating participants with ongoing EGFR inhibitor-induced rash. Ketoconazole may reduce the symptoms related ...

Detailed Description

PRIMARY OBJECTIVES: I. To demonstrate that topical ketoconazole, an anti-androgen, palliates EGFR inhibitor-induced rash within a group of racially diverse cancer patients. II. To explore the role o...

Eligibility Criteria

Inclusion

  • Patient has developed a rash or symptoms of a rash (cutaneous burning) characteristic of an EGFR inhibitor (health-care provider report of the rash with no other documentation is permitted)
  • Patient is anticipated to continue for at least 28 days with an EGFR inhibitor or restart =\< 14 days of registration and continue for at least 28 days
  • Mayo only: Patient is willing to provide a skin biopsy for correlative research; Note: Can be waived with permission of study chair (documentation such as an email must be provided)
  • Patient must complete baseline quality of life (QOL) packet

Exclusion

  • Patient has a prior allergy or intolerance of ketoconazole
  • Patient has an allergy or intolerance to sulfites

Key Trial Info

Start Date :

September 25 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 15 2024

Estimated Enrollment :

58 Patients enrolled

Trial Details

Trial ID

NCT03471364

Start Date

September 25 2018

End Date

September 15 2024

Last Update

October 8 2025

Active Locations (6)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (6 locations)

1

Carle on Vermilion

Danville, Illinois, United States, 61832

2

Carle Cancer Center

Urbana, Illinois, United States, 61801

3

Mayo Clinic in Rochester

Rochester, Minnesota, United States, 55905

4

Park Nicollet Frauenshuh Cancer Center

Saint Louis Park, Minnesota, United States, 55426

Ketoconazole in Treating Participants With Ongoing EGFR Inhibitor-Induced Rash | DecenTrialz